|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Table S2. Characteristics of subgroups and restricted cohorts of patients with autoimmune hepatitis (AIH) at beginning of follow-up.** | | | | | | | | | | | | | | | |
|  | *Subgroups and restricted cohorts of AIH patients – within the 1805 included AIH patients* | | | | | | | | | | | | | |  |
| **IST** | | | **Biopsy** | | | | **IST and biopsy** | | | | | **Recorded ALT** | | **Index date** |
| *With* | *Without* | | *With* | | *Without* | | *With* | | | *Without* | | *With* | *Without* |  |
| *N = 1486* | *N = 319* | | *N = 1361* | | *N = 444* | | *N = 1225* | | | *N = 580* | | *N = 569* | *N = 1236* | *N = 2545* |
| Follow-up (years)*,*  *median (IQR)* | 6.3 (3.1-11.4) | 6.7 (3.1-12.7) | | 6.4 (3.2-11.8) | | 6.2 (3.1-10.6) | | 6.4 (3.3-11.7) | | | 6.3 (3.1-11.2) | | 3.1 (1.9-5.1) | 9.0 (5.2-14.0) | 6.4 (3.1-11.5) |
| Female, *(%)* | 1085 (73.0) | 224 (70.2) | | 982 (72.2) | | 327 (73.7) | | 885 (72.2) | | | 424 (73.1) | | 397 (69.8) | 912 (73.8) | 1818 (71.4) |
| Age (years)*,*  *median (IQR)* | 53.0 (35.1-64.8) | 51.2 (34.0-63.7) | | 52.2 (34.4-63.8) | | 54.2 (36.6-66.4) | | 52.3 (34.6-64.1) | | | 53.6 (35.5-65.9) | | 51.4 (32.3-64.8) | 53.2 (36.1-64.2) | 52.4 (35.2-64.6) |
| Alc.diag., *(%)* | 41 (2.8) | 22 (6.9) | | 39 (2.9) | | 24 (5.4) | | 31 (2.5) | | | 32 (5.5) | | 23 (4.0) | 40 (3.2) | 121 (4.8) |
| COPD, *(%)* | 45 (3.0) | 6 (1.9) | | 35 (2.6) | | 16 (3.6) | | 32 (2.6) | | | 19 (3.3) | | 19 (3.3) | 32 (2.6) | 84 (3.3) |
| Cirrhosis, *(%)* | 385 (25.9) | 38 (11.9) | | 359 (26.4) | | 64 (14.4) | | 338 (27.6) | | | 85 (14.7) | | 99 (17.4) | 324 (26.2) | 605 (23.8) |
| IST, *(%)* | 1486 (100) | 0 (0) | | 1225 (90.0) | | 261 (58.8) | | 1225 (100) | | | 261 (45.0) | | 476 (83.7) | 1010 (81.7) | 1846 (72.5) |
|  | | | | | | | | | | | | | | | |
|  | *Restricted cohorts of AIH patients – within the 569 included AIH patients with a recorded ALT measurement* | | | | | | | | | | | | | |  |
| **ALT peak (1xUNL)** | | | | **ALT peak (2xUNL)** | | | | **IST, biopsy and**  **ALT peak (1xUNL)** | | | | **IST, biopsy and**  **ALT peak (2xUNL)** | | **AIH and CRC** |
| *With* | | *Without* | | *With* | | *Without* | | | *With* | | *Without* | *With* | *Without* |  |
| *N = 501* | | *N = 68* | | *N = 423* | | *N = 146* | | | *N = 365* | | *N = 204* | *N = 329* | *N = 240* | *N = 21* |
| Follow-up (years)*,*  *median (IQR)* | 3.1 (1.9-5.2) | | 3.1 (1.9-4.9) | | 3.1 (1.9-5.3) | | 3.1 (1.9-4.8) | | | 3.2 (2.0-5.3) | | 3.1 (1.8-4.8) | 3.1 (2.0-5.2) | 3.1 (1.8-5.1) | 4.2 (2.2-5.4) |
| Female, *(%)* | 352 (70.3) | | 45 (66.2) | | 298 (70.5) | | 99 (67.8) | | | 251 (68.8) | | 146 (71.6) | 227 (69.0) | 170 (70.8) | 11 (52.4) |
| Age (years)*,*  *median (IQR)* | 50.3 (32.1-64.4) | | 60.3 (36.9-67.5) | | 50.1 (31.0-63.7) | | 57.7 (40.3-68.4) | | | 50.3 (31.7-64.0) | | 53.8 (33.0-66.4) | 49.9 (30.5-62.6) | 54.2 (34.8-67.3) | 63.8 (58.1-70.6) |
| Alc.diag., *(%)* | 18 (3.6) | | 5 (7.4) | | 13 (3.1) | | 10 (6.9) | | | 9 (2.5) | | 14 (6.9) | 7 (2.1) | 16 (6.7) | 0 (0) |
| COPD, *(%)* | >14 (3.0-3.6) | | <5 (<7.4) | | 14 (3.3) | | 5 (3.4) | | | 9 (2.5) | | 10 (4.9) | 8 (2.4) | 11 (4.6) | <5 (<23.8) |
| Cirrhosis, *(%)* | 86 (17.2) | | 13 (19.1) | | 68 (16.1) | | 31 (21.2) | | | 73 (20.0) | | 26 (12.8) | 62 (18.8) | 37 (15.4) | 9 (42.9) |
| IST, *(%)* | 430 (85.8) | | 46 (67.7) | | 377 (89.1) | | 99 (67.8) | | | 365 (100) | | 111 (54.4) | 329 (100) | 147 (61.3) | >17 (>81.0) |
| **Abbreviations:** ALT, alanine aminotransferase; UNL, Upper normal limit; ALT peak, ALT measurement above the upper limit of the normal reference interval (men: ≥70U/l, women: ≥45U/l [40]); IQR, interquartile range (i.e. 25th–75th percentile); Alc.diag., Alcohol-related diagnoses; COPD, Chronic obstructive pulmonary disease; IST, immunosuppressive treatment; CRC, colorectal cancer.  **Note:** Cells containing numbers of less than 5 are shown as ‘<5’ to ensure patient anonymity. | | | | | | | | | | | | | | | |